http://www.fpnotebook.com/
LeishmaniasisAka: Leishmania, Kala Azar, Leishmania donovani
- History
- First reported in 1903 by both Leishman and Donovan
- Epidemiology
- Incidence
- Worldwide: Up to 2 million new cases per year
- United States: Up to 100 cases/year (New World)
- Endemic Areas
- South-Central Texas
- Mexico and Central America
- South America (most common source for U.S. traveler)
- Most commonly contracted in Peru and Brazil
- No cases in Uruguay or Chile
- Middle East
- Africa
- Asia
- Pathophysiology
- Vector
- Transmitted by Sandflies
- Old World Genus: Phlebotomus
- New World Genus: Lutzomyia
- Sandfly is 2 mm long, hairy fly
- Not stopped by Mosquito netting
- Breeds in manure, rodent holes, leaf debris
- Leishmaniasis parasite
- Promastigote (Infectious form)
- Motile form of parasite with anterior flagellum
- Develops in sandfly over 10 days
- Transmitted to humans via sandfly bite
- Macrophages ingest promastigote
- Shifts to amastigote form to endure acidic lysosome
- Amastigote (Disease causing form)
- Non-motile, obligate intracellular parasite
- Diameter up to 7 microns
- Results in disease and decreased cellular immunity
- Sandfly ingests amastigote form when feeding
- Types
- Some species cause visceral and Cutaneous Leishmaniasis
- Visceral Leishmaniasis (Kala Azar)
- Cause
- Leishmania donovani
- Description
- Incubation 3 months
- Cutaneous Leishmaniasis
- See Cutaneous Leishmaniasis
- Symptoms
- Irregular Recurrent Fever
- Weakness
- Sweating
- Cough
- Nausea or Vomiting
- Diarrhea
- Weight loss
- Signs
- Splenomegaly
- Hepatomegaly
- Lymphadenopathy
- Labs
- Complete Blood Count
- Leukopenia
- Anemia
- Pancytopenia
- Liver Function Tests
- Hypoalbuminemia
- Diagnosis: Visceral Leishmaniasis
- Culture, Biopsy, or buffy coat stain
- Skin lesion
- Bone Marrow
- Lymph node
- Complications
- Cirrhosis develops in 10% of visceral leishmaniasis
- Visceral leishmaniasis is fatal without treatment
- Management: Visceral Leishmaniasis
- See Cutaneous Leishmaniasis
- Sodium Antimony Gluconate
- Initial Course
- Adult: 10 mg/kg IV/IM qd x20-30 days
- Child: 20 mg/kg IV/IM qd x20-30 days
- Relapse
- Treat for 40-60 days
- Resistant Cases
- Amphotericin B 0.5 - 1 mg/kg qod for 5-25 weeks
- Pentamidine 3-4 mg/kg qod for 5-25 weeks
- Resources
- Visceral Leishmaniasis
- http://www.geocities.com/donovanivl/
- Prevention
- See Prevention of Vector-borne Infection
- Insect Repellant
- References
- Pearson (1996) Clin Infect Dis 22:1
- Tobin (2001) Am Fam Physician 63(2):326
Genus: Leishmania (C0023270)
|
|---|
| Definition (CSP) | genus of flagellate protozoa comprising several species that are pathogenic for humans; organisms have an amastigote and a promastigote stage in their life cycles; genus has been divided into two subgenera: Leishmania leishmania and Leishmania viannia. |
| Definition (MSH) | A genus of flagellate protozoa comprising several species that are pathogenic for humans. Organisms of this genus have an amastigote and a promastigote stage in their life cycles. As a result of enzymatic studies this single genus has been divided into two subgenera: Leishmania leishmania and Leishmania viannia. Species within the Leishmania leishmania subgenus include: L. aethiopica, L. arabica, L. donovani, L. enrietti, L. gerbilli, L. hertigi, L. infantum, L. major, L. mexicana, and L. tropica. The following species are those that compose the Leishmania viannia subgenus: L. braziliensis, L. guyanensis, L. lainsoni, L. naiffi, and L. shawi. |
| Concepts | Invertebrate (T009)
|
| English | Genus: Leishmania, Leishmania |
| Credits | Derived from the NIH UMLS (Unified Medical Language System)
|
Navigation Tree